NCT02023697 - Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone | Biotech Hunter

Enrollment

391

Participants

Timeline

Start Date

March 10, 2014

Primary Completion Date

March 1, 2017

Study Completion Date

August 9, 2018

Conditions

Prostatic Neoplasms

Interventions

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Trial Locations (68)

100

Taipei

112

Taipei City

333

Guishan Township

2010

Darlinghurst

2145

Westmead

3052

Melbourne

3128

Box Hill

5000

Adelaide

10043

Turin

11733

East Setauket

15215

Pittsburgh

20850

Rockville

20889

Bethesda

28041

Madrid

31008

Pamplona

33907

Fort Myers

40705

Taichung

44805

Nantes

47014

Meldola

48201

Detroit

49241

Busan

52100

Arezzo

54500

Vandœuvre-lès-Nancy

63110

St Louis

68130

Omaha

72076

Tübingen

81362

Kaohsiung City

81675

München

85260

Scottsdale

94805

Villejuif

97239

Portland

3109601

Haifa

4428164

Kfar Saba

4941492

Petah Tikva

5262000

Ramat Gan

7500921

Santiago

8410101

Beersheba

9112001

Jerusalem

06520

New Haven

48109-0330

Ann Arbor

90470 340

Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre

Unknown

Hospital de Clínicas de Porto Alegre, Porto Alegre

01246-000

Instituto do Câncer do Estado de São Paulo, São Paulo

03102 002

IBCC - Instituto Brasileiro de Controle do Cancer, São Paulo

05651-901

Hospital Israelita Albert Einstein, São Paulo

N6A 4L6

London

K1H 8L6

Ottawa

M4N 3M5

Toronto

M5G 2M9

Toronto

H2L 4M1

Montreal

430 12

Chomutov

150 06

Prague

01307

Dresden

00152

Rome

06273

Seoul

05505

Seoul

06591

Seoul

120-752

Seoul

08907

L'Hospitalet de Llobregat

07120

Palma de Mallorca

08025

Barcelona

413 45

Gothenburg

652 30

Karlstad

851 86

Sundsvalls

901 85

Umeå

CH63 4JY

Bebington

TA1 5DA

Taunton

HA6 2RN

Northwood